Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
Multiple Sclerosis Sativex reduced spasticity in MS patients
#1
Sativex reduced spasticity in MS patients

Peter Flachenecker, MD, Head of the Quellenhof Neurological Rehabilitation Center, et al., stated the following in their June 2014 study titled "Long-Term Effectiveness and Safety of Nabiximols (Tetrahydrocannabinol/Cannabidiol Oromucosal Spray) in Clinical Practice," published in European Neurology:

Quote:"Background: Nabiximols (Sativex), in a cannabinoid-based oromucosal spray, is an add-on therapy option for patients with moderate to severe multiple sclerosis spasticity (MSS) resistant to other medications. The study objective was to provide long-term data on clinical outcomes, tolerability, quality of life and treatment satisfaction for MSS patients receiving nabiximols in routine care.

Results: In total, 52 patients were included in the effectiveness analysis after 12 months. The mean spasticity numerical rating scale (NRS, 0-10) score decreased significantly... The majority of patients (84%) did not report adverse events.

Conclusion: Real-life data confirm the long-term effectiveness and tolerability of nabiximols for the treatment of resistant MSS in everyday clinical practice."
June 2014 - Peter Flachenecker, MD
Source: http://medicalmarijuana.procon.org/view....=000884#ms
Reply


Forum Jump:


Users browsing this thread: 1 Guest(s)